文献速递中医内科中药与中成药合理使用

中药注射剂联合卡培他滨与奥沙利铂方案治疗结直肠癌的贝叶斯网络荟萃分析

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis.
PubMed 文献 · Front Pharmacol · 2022-11-29

本研究采用贝叶斯网络荟萃分析,比较不同中药注射剂联合XELOX方案与单用XELOX方案治疗结直肠癌的有效性与安全性。共纳入32项随机对照试验、2847例受试者和11种中药注射剂。结果显示,参麦饮、康莱特和华蟾素注射剂联合XELOX方案在多项结局中表现较优,但结论仍需多中心高质量研究验证。

要点

  • 参麦饮、参麦和康莱特联合XELOX方案的临床有效率最高。
  • 参芪扶正、参麦和鸦胆子油注射剂联合XELOX方案提升CD4+值效果最佳。
  • 康莱特、华蟾素和苦参注射剂联合XELOX方案改善CD4+/CD8+比值最优。

核心结论

  • 参麦饮、康莱特和华蟾素注射剂联合XELOX方案在多项观察指标中表现较其他中药注射剂联合方案更优。
  • 中药注射剂联合XELOX方案总体优于单用XELOX方案。
  • 结论仍需多中心试验和高质量研究进一步支持。

研究设计与样本

  • 研究为贝叶斯网络荟萃分析,检索截至2022年4月的多个电子数据库中的随机对照试验。
  • 共纳入32项合格文献,涉及2847例受试者和11种中药注射剂。
  • 采用Cochrane偏倚风险工具评估纳入随机对照试验的质量。
  • 使用R 4.0.3软件和Stata 15.1软件同时进行标准配对和贝叶斯网络荟萃分析。

主要发现

  • 临床有效率最高的三种中药注射剂联合XELOX方案为参麦饮、参麦和康莱特。
  • 改善CD3+值前三为参麦饮、参芪扶正和华蟾素注射剂联合XELOX方案。
  • 提升CD4+值最佳为参芪扶正、参麦饮和鸦胆子油注射剂联合XELOX方案。
  • 改善CD4+/CD8+比值最佳为康莱特、华蟾素和苦参注射剂联合XELOX方案。
  • 改善体能状态前三为消癌平、参麦和康莱特注射剂联合XELOX方案。

关键数值与推荐

  • 提升CD8+值最佳为华蟾素和鸦胆子油注射剂联合XELOX方案。
  • 改善胃肠道反应最佳为参芪扶正、康艾和苦参注射剂联合XELOX方案。
  • 改善白细胞减少前三为参芪扶正、复方苦参和康莱特注射剂联合XELOX方案。
  • 改善血小板下降前三为复方苦参、华蟾素和参芪扶正注射剂联合XELOX方案。
  • 改善恶心呕吐最佳为华蟾素、复方苦参和艾迪注射剂联合XELOX方案。

临床怎么用

  • 临床可优先考虑参麦饮、康莱特或华蟾素注射剂联合XELOX方案以提升有效率。
  • 针对免疫功能改善,可根据目标指标选择参芪扶正、参麦饮或苦参等注射剂联合XELOX方案。
  • 针对化疗相关不良反应,可参考对应结局排名选择中药注射剂联合XELOX方案。

局限性

  • 结论需多中心试验和高质量研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: The aim of the present Bayesian network meta-analysis (NMA) was to explore the comparative effectiveness and safeaty of different Chinese Medicine injections (CMIs) combined with the XELOX regimen versus XELOX alone for colorectal cancer (CRC). Methods: A comprehensive search for randomized controlled trials (RCTs) was performed with regard to different CMIs for the treatment of CRC in several electronic databases up to April 2022. The quality assessment of the included RCTs was conducted according to the Cochrane risk of bias tool. Standard pair-wise and Bayesian NMA were designed to comparethe effectiveness and safety of different CMIs combined with the XELOX regimen by utilizing R 4.0.3 software and Stata 15.1 software simultaneously. Results: Initially, a total of 4296 citations were retrieved through comprehensive searching, and 32 eligible articles involving 2847 participants and 11 CMIs were ultimately included. CMIs combined with XELOX were superior to the XELOX regimen alone, and a total of ten Observation Indicators were included in the study, with the following results. Among all the injections, Shengmaiyin, Shenmai, and Kanglaite combined with the XELOX regimen were the three CMIs with the highest clinical efficiency. The top three in terms of improving CD3+ values were Shengmaiyin, Shenqifuzheng, and Cinobufacini injections. Shenqifuzheng, Shengmaiyin, and BruceaJavanica oil injections combined with the XELOX regimen performed best at raising CD4+ values. Kanglaite, Cinobufacini, and Matrine injections combined with the XELOX regimen performed best in improving CD4+/CD8+ rates. The top three in terms of improving performance status were Xiaoaiping, Shenmai, and Kanglaite injections. Cinobufacini and Brucea Javanica oil injections combined with the XELOX regimen performed best at raising CD8+ values. Shenqifuzheng, Kangai, and Matrine injections combined with the XELOX regimen performed best in improving Gastrointestinal reactions.The top threein terms of improving Leukopenia were Shenqifuzheng, Compound Kushen and Kanglaite injections. The top three in terms of improving Platelet decline were Compound Kushen, Cinobufacini and Shenqifuzheng injections. Additionally, those that were best at improving nausea and vomitting were Cinobufacini, Compound Kushen and Aidi injections. Conclusion: The results of the analysis demonstrated thatShengmaiyin, Kanglaite, and Cinobufacini injections and the XELOX regimen were associated with morepreferable and beneficial outcomes than other CMI groups. Nevertheless, additional results from multicenter trials and high-quality studies will bevital to support our findings. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=326097, CRD42022326097.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Liu S, Zhang K, Hu X, et al. Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis. Front Pharmacol. 2022. PMID: 36523501. doi:10.3389/fphar.2022.1004259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。